Vnitr Lek 2013, 59(9):819-827

Recommendation of the Czech society of Endocrinology for the treatment of Cushing's syndrome in adults

M. Kršek1,*, J. Čáp2, V. Hána1, J. Marek1
1 III. interní klinika - klinika endokrinologie a metabolizmu 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA
2 IV. interní hematologická klinika Lékařské fakulty UK a FN Hradec Králové, přednosta doc. MUDr. Pavel Žák, Ph.D.

Cushing's syndrome is a rare disorder with variable aetiology which is connected with significantly increased morbidity and mortality. Therefore, early determination of correct aetiology and early treatment are essential for a decrease of morbidity and mortality of patients. Present article introduces review and current recommendation of Czech Society of Endocrinology for the treatment of Cushing's syndrome.

Keywords: Cushing's syndrome; treatment; recommendation

Published: September 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kršek M, Čáp J, Hána V, Marek J. Recommendation of the Czech society of Endocrinology for the treatment of Cushing's syndrome in adults. Vnitr Lek. 2013;59(9):819-827.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cushing HW. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 1932; 50: 137-195. Go to original source...
    2. Lahera Vargas M, da Costa CV. Prevalence, etiology and clinical findings of Cushing's syndrome. Endocrinol Nutr 2009; 56: 32-39. Go to original source... Go to PubMed...
    3. Bertagna X, Guignat L, Groussin L et al. Cushing's disease. Best Pract Res Clin Endocrinol Metab 2009; 23: 607-623. Go to original source... Go to PubMed...
    4. Ross EJ, Linch DC. Cushing's syndrome-Killing disease: Discriminatory value of signs and symptoms aiding early diagnosis. Lancet 1982; 2: 646-649. Go to original source... Go to PubMed...
    5. Newell-Price J, Trainer P, Bessser M et al. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 1998; 19: 647-672. Go to original source...
    6. Nieman LK, Chrousos GP, Kellner C et al. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 1985; 61: 536-540. Go to original source... Go to PubMed...
    7. Nieman LK, Biller BM, Findling JW et al. The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93: 1526-1540. Go to original source... Go to PubMed...
    8. Utz AL, Swearingen B, Biller BM. Pituitary surgery and postoperative management in Cushing's disease. Endocrinol Metab Clin North Am 2005; 34: 459-478. Go to original source... Go to PubMed...
    9. McCance DR, Besser M, Atkinson AB. Assessment of cure after transsphenoidal surgery for Cushing's disease. Clin Endocrinol 1996; 44: 1-6. Go to original source... Go to PubMed...
    10. Vladyka V, Liščák R, Šimonová G et al. Radiosurgical treatment of hypophyseal adenomas with the gamma knife: results in a group of 163 patients during a 5-year period. Čas Lék Česk 2000; 139: 757-766. Go to PubMed...
    11. de Bruin C, Feelders RA, Lamberts SW et al. Somatostatin and dopamine receptors as targets for medical treatment of Cushing's syndrome. Rev Endocr Metab Disord 2009; 10: 91-102. Go to original source... Go to PubMed...
    12. Kam BL, Teunissen JJ, Krenning EP et al. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2012; 39 (Suppl 1): 103-112. Go to original source... Go to PubMed...
    13. Valimaki M, Pelkonen R, Porkka L et al. Long-term results of adrenal surgery in patients with Cushing's syndrome due to adrenocortical adenoma. Clin Endocrinol (Oxf) 1984; 20: 229-236. Go to original source... Go to PubMed...
    14. Young WF Jr, Thompson GB. Laparoscopic adrenalectomy for patients who have Cushing's syndrome. Endocrinol Metab Clin North Am 2005; 34: 489-499. Go to original source... Go to PubMed...
    15. Berruti A, Terzolo M, Sperone P et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 2005; 12: 657-666. Go to original source... Go to PubMed...
    16. Fassnacht M, Libé R, Kroiss M et al. Adrenocortical carcinoma: a clinician's update. Nature Rev Endocrinol 2011; 7: 323-335. Go to original source... Go to PubMed...
    17. McGahan J, Browning P, Brock J et al. Hepatic ablation using radiofrequency electrocautery. Invest Radiol 1990; 25: 267-270. Go to original source... Go to PubMed...
    18. de Baere T, Dufaux J, Roche A et al. Circulatory alterations induced by intra-arterial injection of iodized oil and emulsions of iodized oil and doxorubicin: experimental study. Radiology 1995; 194: 165-170. Go to original source... Go to PubMed...
    19. Bourdeau I, Lacroix A. Aberrant hormone receptors in adrenal Cushing's syndrome. Curr Opin Endocrinol Diab 2002; 9: 230-236. Go to original source...
    20. Morris D, Grossman A. The medical management of Cushing's syndrome. Ann NY Acad Sci 2002; 970: 119-133. Go to original source... Go to PubMed...
    21. Godboud A, Manavela M, Danilowicz K et al. Cabergoline monotherapy in the long-term treatment of Cushing's disease. Eur J Endocrinol 2010; 165: 709-716. Go to original source... Go to PubMed...
    22. Casulari LA, Naves LA, Mello PA et al. Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm Res 2004; 62: 300-305. Go to original source... Go to PubMed...
    23. Pivonello R, Ferrone D, de Herder WW et al. Dopamine receptor expression and function in corticotroph ectopic tumors. J Clin Endocrinol Metab 2007; 92: 65-69. Go to original source... Go to PubMed...
    24. Valassi E, Klibanski A, Biller BM. Clinical review: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab 2010; 95: 1025-1033. Go to original source... Go to PubMed...
    25. Lamberts SW, Uitterlinden P, Klijn JM. The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease. Acta Endocrinol (Copenh) 1989; 120: 760-766. Go to original source... Go to PubMed...
    26. Hofland LJ, van der Hoek J, Feelders R et al. The multiligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 2005; 152: 645-654. Go to original source... Go to PubMed...
    27. Colao A, Petersenn S, Newell-Price J et al. Pasireotide B2305 Study Group. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med 2012; 366: 914-924. Go to original source... Go to PubMed...
    28. Castillo V, Giacomini D, Paez-Pereda M et al. Retinoic acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology 2006; 147: 4438-4444. Go to original source... Go to PubMed...
    29. Dang CN, Trainer P. Pharmacological management of Cushing's syndrome: an update. Arq Bras Endocrinol Metabol 2007; 51: 1339-1348. Go to original source... Go to PubMed...
    30. Knight TE, Shikuma CY, Knight J. Ketoconazole-induced fulminant hepatitis necessitating liver transplantation. J Am Acad Dermatol 1991; 25: 398-400. Go to original source... Go to PubMed...
    31. Verhelst JA, Trainer PJ, Howlett TA et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf) 1991; 35: 169-178. Go to original source... Go to PubMed...
    32. Haak HR, Hermans J, van de Velde CJ et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in consecutive series of 96 patients. Br J Cancer 1994; 69: 947-951. Go to original source... Go to PubMed...
    33. Allolio B, Schulte HM, Kaulen D et al. Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in Cushing's syndrome. Klin Wochenschr 1988; 66: 361-364. Go to original source... Go to PubMed...
    34. Drake WM, Perry LA, Hinds CJ et al. Emergency and prolonged use of intravenous etomidate to control hypercortisolaemia in a patient with Cushing's syndrome and peritonitis. J Clin Endocrinol Metab 1998; 83: 3542-3544. Go to original source...
    35. Feelders RA, de Bruin C, Pereira AM et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N Engl J Med 2010; 362: 1846-1848. Go to original source... Go to PubMed...
    36. Kršek M, Hána V et al. Cushingův syndrom. Praha: Galén 2006.
    37. Kršek M. Cushingův syndrom a možnosti jeho ř ešení v roce 2012. Remedia 2012; 22: 386-392.
    38. Trainer PJ, Eastment C, Grossman A et al. The relationship between cortisol production rate and serial serum cortisol estimation in patients on medical therapy for Cushing's syndrome. Clin Endocrinol 1993; 39: 441-443. Go to original source... Go to PubMed...
    39. Lindsay JR, Jonklaas J, Oldfield EH et al. Cushing's syndrome during pregnancy: personal experience and review of the literature. J Clin Endocrinol Metab 2005; 90: 3077-3083. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.